Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, hispanics, and non-hispanic whites: The Insulin Resistance Atherosclerosis Study

Circulation

Volumn 107, Issue 19, 2003, Pages 2422-2427

  Festa, Andreas ^a   D'Agostino Jr , Ralph ^b   Rich, Steven S ^b   Jenny, Nancy S ^c   Tracy, Russell P ^c   Haffner, Steven M ^a,d  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Epidemiology; Genetics; Insulin; Plasminogen activator inhibitor

Indexed keywords

GENOMIC DNA; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ALLELE; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DNA POLYMORPHISM; ETHNIC DIFFERENCE; ETHNOLOGY; FEMALE; GENE AMPLIFICATION; GENOTYPE; GLUCOSE TOLERANCE TEST; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; TRIACYLGLYCEROL BLOOD LEVEL;

AFRICAN AMERICANS; AFRICAN CONTINENTAL ANCESTRY GROUP; ARTERIOSCLEROSIS; BODY COMPOSITION; DIABETES MELLITUS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC SCREENING; GENETICS, POPULATION; GENOTYPE; GLUCOSE TOLERANCE TEST; HETEROZYGOTE; HISPANIC AMERICANS; HOMOZYGOTE; HUMANS; INSULIN RESISTANCE; LINEAR MODELS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS);

EID: 0038518463     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000066908.82782.3A     Document Type: Article

References (54)

1. Dawson SJ, Wiman B, Hamsten A, et al. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem. 1993;268:10739-10745.
2. Eriksson P, Kallin B, van't Hooft FM, et al. Allele specific increase in basal transcription of the plasminogen activator inhibitor-1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA. 1995;92: 1851-1855.
3. Ossei-Gerning N, Mansfield MW, Stickland MH. et al. Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. Arterioscler Thromb Vasc Biol. 1997;17:33-37.
4. Margaglione M, Cappucci G, d'Addedda M, et al. PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis. Arterioscler Thromb Vasc Biol. 1998;18:562-567.
5. Brown NJ, Abbas A, Byrne D, et al. Comparative effects of estrogen and angiotensin-converting enzyme inhibition on plasminogen activator inhibitor-1 in healthy postmenopausal women. Circulation, 2002;105: 304-309.
6. Mansfield MW, Stickland MH, Grant PJ. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost. 1995;74:842-847.
7. Panahloo A, Mohamed-Ali V, Lane A, et al. Determinants of plasminogen activator inhibitor-1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor-1 gene. Diabetes. 1995;44:37-42.
8. McCormack LJ, Nagi DK, Stickland MH, et al. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype in Pima Indians: relationship to plasminogen activator inhibitor-1 levels and features of the insulin resistance syndrome. Diabetologia. 1996;39:1512-1518.
9. Matsubara Y, Murata M, Isshiki I, et al. Genotype frequency of plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism in healthy Japanese males and its relation to PAI-1 levels. Int J Hematol. 1999;69:43-47.
10. Boekholdt SM, Bijsterveld NR, Moons AHM, et al. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review. Circulation. 2001;104:3063-3068.
11. Anvari A, Schuster E, Gottsauner-Wolf M, et al. PAI-1 4G/5G polymorphism and sudden cardiac death in patients with coronary artery disease. Thromb Res. 2001;103:103-107.
12. He JQ, Gaur LK, Stempien-Otero A, et al. Genetic variants of the hemostatic system and development of transplant coronary artery disease. J Heart Lung Transplant. 2002;21:629-636.
13. Ortlepp JR, Hoffmann R, Killian A, et al. The 4G/5G promoter polymorphism of the plasminogen activator inhibitor-1 gene and late lumen loss after coronary stent placement in smoking and nonsmoking patients. Clin Cardiol. 2001;24:585-591.
14. Stern MP, Gaskill SP. Secular trends in ischemic heart disease and stroke mortality from 1970-1976 in Spanish-surnamed and other white individuals in Bexar County, Texas. Circulation. 1978;58:537-543.
15. Mitchell BD, Haffner SM, Hazuda HP, et al. Diabetes and coronary heart disease in Mexican Americans. Ann Epidemiol. 1992;2:101-106.
16. Rewers M, Shetterly SM, Baxter J, et al. Prevalence of coronary heart disease in subjects with normal and impaired glucose tolerance and non-insulin dependent diabetes mellitus in a bi-ethnic Colorado population: the San Luis Valley Diabetes Study. Am J Epidemiol. 1992;135:1321-1330.
17. Wei M, Valdez RA, Mitchell BD, et al. Effects of cigarette smoking, diabetes, high cholesterol, and hypertension on all-cause mortality and cardiovascular disease mortality in Mexican Americans: the San Antonio Heart Study. Am J Epidemiol. 1996;144:1058-1065.
18. Gillum FR. Cardiovascular disease in the United States: an epidemiologic overview. Cardiovasc Clin. 1991;21:3-16.
19. Lewis C, Raczynski JB, Oberman A, et al. Risk factors and the natural history of coronary heart disease in blacks. Cardiovasc Clin. 1991;21:29-45.
20. D'Agostino RB Jr, Burke G, O'Leary D, et al. Ethnic differences in carotid wall thickness: the Insulin Resistance Atherosclerosis Study. Stroke. 1996;27:1744-1749.
21. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor-1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia. 1991;34:457-462.
22. Landin K, Stigendal L, Eriksson E, et al. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism. 1990;39:1044-1048.
23. Potter van Loon BJ, Kluft C, Radder JK, et al. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism. 1993;42:945-949.
24. Asplund-Carlson A, Hamsten A, Wiman B, et al. Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men. Diabetologia. 1993;36:817-825.
25. Festa A, D'Agostino R Jr, Mykkänen L, et al. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance: the Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vase Biol. 1999;19:562-568.
26. Festa A, D'Agostino R Jr, Mykkänen L, et al. Low-density lipoprotein particle size is inversely related to plasminogen activator inhibitor-1 levels: the Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol. 1999;19:605-610.
27. Haffner SM, Stern MP, Hazuda HP, et al. Upper body adiposity and centralized adiposity in Mexican American and non-Hispanic whites: relationship to body mass index and other behavioral and demographic variables. Int J Obes. 1986;10:493-502.
28. Stern MP, Rosenthal M, Haffner SM, et al. Sex difference in the effects of sociocultural status on diabetes and cardiovascular risk factors in Mexican Americans: the San Antonio Heart Study. Am J Epidemiol. 1984;120:834-851.
29. Haffner SM, Hazuda HP, Mitchell BD, et al. Increased incidence of type II diabetes mellitus in Mexican Americans. Diabetes Care. 1991;14: 102-108.
30. Haffner SM, Mitchell BD, Stern MP, et al. Decreased prevalence of hypertension in Mexican Americans. Hypertension. 1990;16:226-232.
31. Brancati FL, Kao WH, Folsom AR, et al. Incident type 2 diabetes mellitus in African American and white adults: the Atherosclerosis Risk in Communities Study. JAMA. 2000;283:2253-2259.
32. Freedman DS, Strogatz DS, Eaker E, et al. Differences between black and white men in correlates of high density lipoprotein cholesterol. Am J Epidemiol. 1990;132:656-659.
33. Haffner SM, D'Agostino R Jr, Goff D, et al. LDL size in African Americans, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study. Arterioscler Thromb Vasc Biol. 1999;19:2234-2240.
34. Haffner SM, D'Agostino R Jr, Saad MF, et al. Increased insulin resistance and insulin secretion in non-diabetic African-Americans and Hispanics compared with non-Hispanic whites: the Insulin Resistance Atherosclerosis Study. Diabetes. 1996;45:742-748.
35. Wagenknecht LE, Mayer EJ, Rewers M, et al. The Insulin Resistance Atherosclerosis Study (IRAS): objectives, design and recruitment results. Ann Epidemiol. 1995;5:464-471.
36. World Health Organization. Diabetes Mellitus: Report of a WHO Study Group. Geneva, Switzerland: World Health Organization; 1985. Technical Report Series No. 727.
37. Bergman RN, Finegood DT, Ader M. Assessment of insulin sensitivity in vivo. Endocr Rev. 1985;6:45-86.
38. Pacini G, Bergman RN. MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test. Comput Methods Programs Biomed. 1986;23:113-122.
39. Macy E, Meilahn E, Declerck P, et al. Sample preparation for plasma measurement of plasminogen activator inhibitor-1 antigen in large population studies. Arch Pathol Lab Med. 1993;117:67-70.
40. Declerck P, Collen D. Measurement of plasminogen activator inhibitor 1 (PAI-1) in plasma with various monoclonal antibody-based enzymelinked immunosorbent assays. Thromb Res (Suppl). 1990;10:3-9.
41. Falk G, Almqvist A, Nordenhem A, et al. Allele specific PCR for detection of a sequence polymorphism in the promoter region of the plasminogen activator inhibitor-1 (PAI-1) gene. Fibrinolysis. 1995;9:170-174.
42. Henry M, Tregouet DA, Alessi MC, et al. Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations. Arterioscler Thromb Vasc Biol. 1998;18:84-91.
43. Mansfield MW, Stickland MH, Grant PJ. PAI-1 concentrations in firstdegree relatives of patients with non-insulin-dependent diabetes: metabolic and genetic associations. Thromb Haemost. 1997;77:357-361.
44. Henry M, Chomiki N, Scarabin PY, et al. Five frequent polymorphisms of the PAI-1 gene: lack of association between genotypes, PAI activity, and triglyceride levels in a healthy population. Arterioscler Thromb Vasc Biol. 1997;17:851-858.
45. Viitanen L, Pihlajamäki J, Halonen P, et al. Association of angiotensin converting enzyme and plasminogen activator inhibitor-1 promoter gene polymorphisms with features of the insulin resistance syndrome in patients with premature coronary heart disease. Atherosclerosis. 2001;157:57-64.
46. Cesari M, Rossi GP. Plasminogen activator inhibitor type 1 in ischemic cardiomyopathy. Arterioscler Thromb Vasc Biol. 1999;19:1378-1386.
47. Hooper WC, Lally C, Austin H, et al. The role of the t-PA I/D and PAI-1 4G/5G polymorphisms in African-American adults with a diagnosis of myocardial infarction or venous thromboembolism. Thromb Res. 2000; 99:223-230.
48. Van Harmelen V, Wahrenberg H, Eriksson P, et al. Role of gender and genetic variance in plasminogen activator inhibitor-1 secretion from human adipose tissue. Thromb Haemost. 2000;83:304-308.
49. Frist ST, Taylor HA, Kirk KA, et al. Expression of PAI-1, t-PA and u-PA in cultured human umbilical vein endothelial cells derived from racial groups. Thromb Res. 1995;77:279-290.
50. McCormack LJ, Semple JI, Stickland MH, et al. The effect of number of days in culture and plasminogen activator inhibitor-1 (PAI-1) 4G/5G genotype on PAI-1 antigen release by cultured human umbilical vein endothelial cells. Thromb Res. 1998;92:199-206.
51. Grenett HE, Benza RL, Li XN, et al. Expression of plasminogen activator inhibitor type I in genotyped human endothelial cell cultures: genotype-specific regulation by insulin. Thromb Haemost. 1999;82:1504-1509.
52. Cesari M, Sartori MT, Patrassi GM, et al. Determinants of plasma levels of plasminogen activator inhibitor-1 (PAI-1): a study of normotensive twins. Arterioscler Thromb Vasc Biol. 1999;19:316-320.
53. Festa A, D'Agostino R Jr, Tracy RP, et al. Levels of acute phase proteins and plasminogen activator inhibitor-1 in relation to the development of type 2 diabetes mellitus: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes. 2002;51:1131-1137.
54. Harris MI. Non-insulin dependent diabetes mellitus in black and white Americans. Diabetes Metab Rev. 1990;6:71-90.